Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
disseminated fusarium infection following cladribine chemotherapy for hairy cell leukaemia
Original title: “Disseminated Fusarium infection following cladribine chemotherapy for hairy-cell leukaemia.”
hairy cell leukemia 2026 update on diagnosis risk stratification and treatment
Original title: “Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk-Stratification, and Treatment.”
braf v600e mutated marginal zone lymphoma may exhibit features that partially overlap with hairy cell leukemia
Original title: “BRAF V600E-mutated marginal zone lymphoma may exhibit features that partially overlap with hairy cell leukemia.”
real world treatment and outcomes in hairy cell leukemia a multicenter retrospective cohort including braf inhibitor therapy
Original title: “Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.”
zanubrutinib in hairy cell leukemia variant clinical report and overview of btk inhibition in variant disease
Original title: “Zanubrutinib in Hairy Cell Leukemia Variant: Clinical Report and Overview of BTK Inhibition in Variant Disease.”
updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia hcl and hcl variant
Original title: “Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.”